OBJECTIVES: To determine whether co-administration of soy during tibolone treatment would prevent tibolone-induced dyslipoproteinemia in postmenopausal monkeys and women. METHODS:Surgically postmenopausal cynomolgus monkeys (n = 18) were assigned randomly to one of four dietary regimens in a Latin Square crossover design, such that all animals received all diets for 14 weeks with a 4-week washout period: (1) casein/lactalbumin (CL); (2) tibolone (Tib, 1.25 mg/day women's equivalent); (3) soy (138 mg isoflavones/day women's equivalent); (4) Soy + Tib. Postmenopausal women ontibolone treatment were randomized to receive soy powder (52 g of soy protein containing 112 mg isoflavones) or placebo (containing 52 g of milk protein) daily in a crossover trial for 8 weeks with a 4-week washout period. RESULTS: Monkeys given Tib alone had approximately 14% increase in plasma LDL + VLDL-C; whereas those given soy combined with tibolone had significant ( approximately 22%) reductions. Tib treated monkeys had reductions in plasma HDL-C of about 48% vs. no reductions in Soy + Tib. In postmenopausal women usingtibolone, soy reduced plasma LDL-C concentrations by approximately 10% from baseline without a change in HDL-C. CONCLUSIONS:Co-administration of soy during tibolone treatment improved the lipoprotein profile in both monkeys and women; however, the effects were more robust in monkeys.
RCT Entities:
OBJECTIVES: To determine whether co-administration of soy during tibolone treatment would prevent tibolone-induced dyslipoproteinemia in postmenopausal monkeys and women. METHODS: Surgically postmenopausal cynomolgus monkeys (n = 18) were assigned randomly to one of four dietary regimens in a Latin Square crossover design, such that all animals received all diets for 14 weeks with a 4-week washout period: (1) casein/lactalbumin (CL); (2) tibolone (Tib, 1.25 mg/day women's equivalent); (3) soy (138 mg isoflavones/day women's equivalent); (4) Soy + Tib. Postmenopausal women on tibolone treatment were randomized to receive soy powder (52 g of soy protein containing 112 mg isoflavones) or placebo (containing 52 g of milk protein) daily in a crossover trial for 8 weeks with a 4-week washout period. RESULTS: Monkeys given Tib alone had approximately 14% increase in plasma LDL + VLDL-C; whereas those given soy combined with tibolone had significant ( approximately 22%) reductions. Tib treated monkeys had reductions in plasma HDL-C of about 48% vs. no reductions in Soy + Tib. In postmenopausal women using tibolone, soy reduced plasma LDL-C concentrations by approximately 10% from baseline without a change in HDL-C. CONCLUSIONS: Co-administration of soy during tibolone treatment improved the lipoprotein profile in both monkeys and women; however, the effects were more robust in monkeys.
Authors: D J Jenkins; C W Kendall; E Vidgen; V Vuksan; C J Jackson; L S Augustin; B Lee; M Garsetti; S Agarwal; A V Rao; G B Cagampang; V Fulgoni Journal: Metabolism Date: 2000-11 Impact factor: 8.694
Authors: D J Jenkins; C W Kendall; M Garsetti; R S Rosenberg-Zand; C J Jackson; S Agarwal; A V Rao; E P Diamandis; T Parker; D Faulkner; V Vuksan; E Vidgen Journal: Metabolism Date: 2000-04 Impact factor: 8.694
Authors: G J Wang; O Lapcík; R Hampl; M Uehara; N Al-Maharik; K Stumpf; H Mikola; K Wähälä; H Adlercreutz Journal: Steroids Date: 2000-06 Impact factor: 2.668
Authors: H Wiseman; J D O'Reilly; H Adlercreutz; A I Mallet; E A Bowey; I R Rowland; T A Sanders Journal: Am J Clin Nutr Date: 2000-08 Impact factor: 7.045
Authors: Yvonne T van der Schouw; Anouk Pijpe; Corinne E I Lebrun; Michiel L Bots; Petra H M Peeters; Wija A van Staveren; Steven W J Lamberts; Diederick E Grobbee Journal: Arterioscler Thromb Vasc Biol Date: 2002-08-01 Impact factor: 8.311
Authors: Siying S Li; Sonia Blanco Mejia; Lyubov Lytvyn; Sarah E Stewart; Effie Viguiliouk; Vanessa Ha; Russell J de Souza; Lawrence A Leiter; Cyril W C Kendall; David J A Jenkins; John L Sievenpiper Journal: J Am Heart Assoc Date: 2017-12-20 Impact factor: 5.501